New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Understanding lung cancer

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than
Oncology December 17,2023
Understanding lung cancer

Understanding lung cancer

by Jason HowlandCredit: Pixabay/CC0 Public DomainNovember is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer deaths worldwide. Each year, more people die from lung cancer than
Oncology December 17,2023
UGN-101 reviewed in real-world upper tract urothelial cancer setting

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online
Oncology December 17,2023
UGN-101 reviewed in real-world upper tract urothelial cancer setting

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online
Oncology December 17,2023
Talazoparib + enzalutamide beneficial in metastatic prostate cancer

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according
Oncology December 17,2023
Talazoparib + enzalutamide beneficial in metastatic prostate cancer

Talazoparib + enzalutamide beneficial in metastatic prostate cancer

by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according
Oncology December 17,2023
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

byUniversity of Texas M. D. Anderson Cancer CenterAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainIn the Phase I/II CodeBreaK 100 trial
World medicine December 17,2023
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

byUniversity of Texas M. D. Anderson Cancer CenterAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainIn the Phase I/II CodeBreaK 100 trial
World medicine December 17,2023
Slit2 signaling stimulates Ewing sarcoma growth

Slit2 signaling stimulates Ewing sarcoma growth

by Impact Journals LLCEWS::FLI1 binds to the Slit2 gene promoter in Ewing sarcoma cells. Credit: 2022 Suvarna et al.A new research paper was published inGenes & Canceron December 14, 2
Oncology December 17,2023
Slit2 signaling stimulates Ewing sarcoma growth

Slit2 signaling stimulates Ewing sarcoma growth

by Impact Journals LLCEWS::FLI1 binds to the Slit2 gene promoter in Ewing sarcoma cells. Credit: 2022 Suvarna et al.A new research paper was published inGenes & Canceron December 14, 2
Oncology December 17,2023
Seeking leukemia's Achilles heel

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h
Oncology December 17,2023
Seeking leukemia's Achilles heel

Seeking leukemia's Achilles heel

byAmerican Society for Biochemistry and Molecular BiologyGraphical abstract. Credit:Molecular & Cellular Proteomics(2023). DOI: 10.1016/j.mcpro.2023.100503A team of researchers h
Oncology December 17,2023
Inequities seen in cancer treatment delay in patients with SARS-CoV-2

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom
Oncology December 17,2023
Inequities seen in cancer treatment delay in patients with SARS-CoV-2

Inequities seen in cancer treatment delay in patients with SARS-CoV-2

by Elana GotkineRace and ethnicity and area-level social determinants of health (SDOH) are associated with delayed or discontinued cancer treatment among patients with severe acute respiratory syndrom
Oncology December 17,2023
SABCS: Updated analysis confirms endocrine therapy effective with/without chemo

SABCS: Updated analysis confirms endocrine therapy effective with/without chemo

by Elana GotkineFor patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS)
Oncology December 17,2023
SABCS: Updated analysis confirms endocrine therapy effective with/without chemo

SABCS: Updated analysis confirms endocrine therapy effective with/without chemo

by Elana GotkineFor patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative early breast cancer (EBC) with a 21-gene recurrence score (RS)
Oncology December 17,2023
Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to
Oncology December 17,2023
Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to
Oncology December 17,2023
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainThe highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses ac
Oncology December 17,2023
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainThe highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses ac
Oncology December 17,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com